|
|
|
|
LEADER |
00000cam a2200000Ma 4500 |
001 |
EBOOKCENTRAL_ocn642841321 |
003 |
OCoLC |
005 |
20240329122006.0 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
070411s2005 si a ob 001 0 eng d |
040 |
|
|
|a DKU
|b eng
|e pn
|c DKU
|d OCLCQ
|d OCLCF
|d OCLCO
|d OCLCQ
|d EBLCP
|d OCLCQ
|d MERUC
|d OCLCQ
|d U3W
|d ICG
|d OCLCQ
|d DKC
|d OCLCQ
|d LEAUB
|d AU@
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
019 |
|
|
|a 935232561
|a 1086530432
|
020 |
|
|
|a 9812569200
|q (electronic bk.)
|
020 |
|
|
|a 9789812569202
|q (electronic bk.)
|
029 |
1 |
|
|a AU@
|b 000049007419
|
029 |
1 |
|
|a DEBBG
|b BV044083423
|
035 |
|
|
|a (OCoLC)642841321
|z (OCoLC)935232561
|z (OCoLC)1086530432
|
050 |
|
4 |
|a RC280.P7 ǂb P75835 2005eb
|
082 |
0 |
4 |
|a 616.99/463
|2 22
|
049 |
|
|
|a UAMI
|
245 |
0 |
0 |
|a Prostate cancer :
|b basic mechanisms and therapeutic approaches /
|c editor, Chawnshang Chang.
|
246 |
3 |
0 |
|a Basic mechanisms and therapeutic approaches
|
260 |
|
|
|a Singapore ;
|a Hackensack, N.J. :
|b World Scientific,
|c ©2005.
|
300 |
|
|
|a 1 online resource (xx, 429 pages) :
|b illustrations (some color)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
|
|a List of Contributors and Affiliations; Preface; Editor -- Chawnshang Chang, Ph. D.; 1 Hormonal Therapy for Prostate Cancer: Clinical and Experimental Evidence Hiroshi Miyamoto and Chawnshang Chang; Introduction; The AR and Androgens; Strategies of Androgen Deprivation; Surgical Castration; Medical Castration; Diethylstilbestrol (DES); LH-RH Agonists and Antagonists; Combined Androgen Blockade (CAB); Antiandrogen Monotherapy; Flutamide; Nilutamide; Bicalutamide; CPA; Neoadjuvant/Adjuvant Hormonal Therapy with Radical Prostatectomy; Neoadjuvant Hormonal Therapy.
|
505 |
8 |
|
|a Adjuvant Hormonal TherapyHormonal Therapy with Radiation Therapy/ Brachytherapy/ Chemotherapy; Radiation Therapy; Brachytherapy; Chemotherapy; Intermittent Androgen Deprivation; 5 -Reductase Inhibitors; Concluding Remarks; References; 2 Immunotherapies for Prostate Cancer Kelley M. Harsch, Jason E. Tasch and Warren D.W. Heston; Introduction; Inflammation; The Immune System; Targets of Immunotherapy; Cytokines; Growth Factors; Tumor Antigens; Monoclonal Antibody Therapy; Modulation of T-Cells; Vaccines; T-Bodies; Summary; References.
|
505 |
8 |
|
|a 3 Radiation Therapy and Hormonal Therapy for Prostate Cancer Ralph A. BrasacchioIntroduction; Conventional and Conformal Radiation Therapy; Localized Prostate Cancer; Radiation Therapy With or Without Androgen Ablation Therapy; Hormone Therapy and Brachytherapy; Potential Mechanisms of Androgen Ablation and Radiation Therapy; Future Directions; References; 4 Gene Therapy for Prostate Cancer Juan Antonio Jimenez, Chinghai Kao, Sang-Jin Lee, Chaeyong Jung and Thomas A. Gardner; Introduction; Gene Therapy Strategy; Tissue-Specific Promoters; Osteocalcin Promoter.
|
505 |
8 |
|
|a Prostate-Specific Enhancer SequenceHuman Telomerase Promoter; Past Approaches; Corrective Gene Therapy; p53; p16; c-myc; Cytoreductive Gene Therapy; Oncolytic Virus Therapy; Pro-drug Enzyme Gene Therapy; Suicide Gene Therapy; Immunotherapy; GM-CSF; IL-2; Future Directions; Conclusion; References; 5 Chemotherapy for Prostate Cancer Samuel K. Kulp, Kuen-Feng Chen and Ching-Shih Chen; Introduction; Present Chemotherapies for HRPC; Mitoxantrone-Based Regimens; Estramustine Phosphate/Antimicrotubule Agent Combinations; Future Therapies for HRPC; PI3K/Akt Signaling Pathway.
|
505 |
8 |
|
|a Receptor Tyrosine KinasesEpidermal Growth Factor Receptor (EGFR) Family; Platelet-Derived Growth Factor Receptor (PDGFR) Family; Tropomyosin Receptor Kinase (trk) Family; Vascular Endothelial Growth Factor Receptors (VEGFR); Ras; PDK-1/Akt; mTOR; Conclusions; References; 6 Chemoprevention for Prostate Cancer Noahiro Fujimoto; Introduction; Chemopreventive Agents, Rationale and Clinical Trials; Sex Steroid Signaling: Antiandrogens and Antiestrogens; 5- Reductase Inhibitor (Finasteride); Antiestrogen and Selective Estrogen Receptor Modulators (SERMs); Phytoestrogens; SERMs.
|
520 |
|
|
|a Prostate cancer is the second leading cause of death in men and its progression is highly dependent on androgens and androgen receptors. However, even with treatment, eventually most prostate cancers progress. Studies of the mechanisms behind this progression leads to advances in treatments for androgen-related diseases. Our book discusses recent prostate cancer research, which includes the following topics: immunotherapy and chemotherapy; radiation, gene, hormonal, and androgen ablation therapies; basic mechanisms behind prostate cancer growth; how mechanisms can be used to treat prostate can.
|
588 |
0 |
|
|a Print version record.
|
590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
650 |
|
0 |
|a Prostate
|x Cancer.
|
650 |
|
2 |
|a Prostatic Neoplasms
|
650 |
|
6 |
|a Prostate
|x Cancer.
|
650 |
|
7 |
|a Prostate
|x Cancer
|2 fast
|
700 |
1 |
|
|a Chang, Chawnshang,
|d 1955-
|1 https://id.oclc.org/worldcat/entity/E39PCjGThVXj3MCfhhTgT7Frhd
|
710 |
2 |
|
|a World Scientific (Firm)
|
758 |
|
|
|i has work:
|a Prostate cancer (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFxV6dfgdpyxKcrYpCVm7d
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
776 |
0 |
8 |
|i Print version:
|a Chang, Chawnshang.
|t Prostate Cancer : Basic Mechanisms And Therapeutic Approaches.
|d River Edge : World Scientific Publishing Company, ©2004
|z 9789812560674
|
856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=259251
|z Texto completo
|
938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL259251
|
994 |
|
|
|a 92
|b IZTAP
|